RTP Mobile Logo
Oncology Grand Rounds Series: Part 10 — PARP Inhibition in the Management of Common Cancers (Faculty Presentations)
Released September 2020

Featuring slide presentations and related discussion from Dr Emmanuel S Antonarakis, Ms Jamie Carroll, Ms Erika Meneely, Dr Kathleen Moore, Dr Joyce O’Shaughnessy, Dr Michael J Pishvaian, Ms Tammy Triglianos and Ms Deborah Wright. (Video Program)

CE Disclosures and Faculty Information

    This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of cancer.

    By providing information on the latest research developments in the context of expert perspectives, this CNE (NCPD) activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with cancer.


    • Comprehend how DNA damage repair pathway abnormalities can be exploited with PARP inhibition to elicit therapeutic benefit for patients with various cancers, including ovarian cancer, breast cancer, pancreatic adenocarcinoma and prostate cancer.
    • Understand the correlation between BRCA1/2 mutations and the development of hereditary cancers, and counsel patients with these genetic abnormalities regarding their long-term outlook and therapeutic options.
    • Assess available and emerging clinical trial data with and FDA indications for the various PARP inhibitors used for ovarian cancer, and develop strategies to identify patients for whom this approach might be appropriate.
    • Recognize the FDA-endorsed indications for the commercially available PARP inhibitors in the management of metastatic breast cancer, and discern how these agents can be optimally employed in nonresearch patient care.
    • Advise patients with metastatic pancreatic adenocarcinoma found to harbor a germline BRCA mutation about recently presented clinical trial findings documenting the efficacy of PARP inhibitor maintenance therapy after first-line platinum-based chemotherapy.
    • Describe the rationale for testing patients with metastatic prostate cancer for BRCA1/2 or other related mutations, and advise appropriate individuals found to harbor these genetic abnormalities about available clinical research data documenting the efficacy of PARP inhibition.
    • Assess the pharmacologic, pharmacodynamic and pharmacokinetic similarities and differences among the commercially available and investigational PARP inhibitors to better understand the activity and toxicities associated with these agents.

    Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

    CNE credit is no longer available for this issue

    CNE credit is no longer available for this issue

    Video Program: This CNE activity consists of a video component.
    CNE credit is no longer available for this issue

    RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CNE (NCPD) activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Emmanuel S Antonarakis, MD
    Professor of Oncology and Urology
    Johns Hopkins University
    The Sidney Kimmel Comprehensive Cancer Center
    Baltimore, Maryland

    Consulting Agreements: Amgen Inc, Astellas, Clovis Oncology, Dendreon Pharmaceuticals Inc, ESSA Pharma Inc, Janssen Biotech Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Sanofi Genzyme; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Dendreon Pharmaceuticals Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc, Johnson & Johnson Pharmaceuticals, Merck, Novartis, Sanofi Genzyme, Tokai Pharmaceuticals Inc; Other Remunerated Activities: Licensed patented technology to QIAGEN.

    Jamie Carroll, APRN, MSN, CNP
    Mayo Clinic
    Rochester, Minnesota

    No financial interests or affiliations to disclose.

    Erika Meneely, APRN, BC
    Massachusetts General Hospital Cancer Center
    Boston, Massachusetts

    No financial interests or affiliations to disclose.

    Kathleen Moore, MD
    The Virginia Kerley Cade Endowed Chair in Cancer Development
    Associate Director, Clinical Research
    Director, Oklahoma TSET Phase I Program
    Stephenson Cancer Center
    Associate Professor, Section of Gynecologic Oncology
    Director, Gynecologic Oncology Fellowship
    Department of Obstetrics and Gynecology
    University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma

    Advisory Committee: AbbVie Inc, Aravive Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Genentech, a member of the Roche Group, GlaxoSmithKline, ImmunoGen Inc, Merck, Mereo BioPharma, Tarveda Therapeutics, Tesaro, A GSK Company, Vavotar Life Sciences; Contracted Research: Clovis Oncology, Genentech, a member of the Roche Group, Merck, PTC Therapeutics; Employment: GOG Foundation/Partners.

    Joyce O’Shaughnessy, MD
    Celebrating Women Chair in Breast Cancer Research
    Baylor University Medical Center
    Director, Breast Cancer Research Program
    Texas Oncology
    US Oncology
    Dallas, Texas

    Advisory Committee and Consulting Agreements: AbbVie Inc, Agendia Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Eisai Inc, Genentech, a member of the Roche Group, Genomic Health Inc, Grail Inc, Halozyme Inc, Heron Therapeutics, Immunomedics Inc, Ipsen Biopharmaceuticals Inc, Jounce Therapeutics, Lilly, Merck, Myriad Genetic Laboratories Inc, Novartis, Odonate Therapeutics, Pfizer Inc, Puma Biotechnology Inc, Roche Laboratories Inc, Seattle Genetics, Syndax Pharmaceuticals Inc.

    Michael J Pishvaian, MD, PhD
    Associate Professor, Department of Oncology
    Director of the Gastrointestinal, Developmental Therapeutics, and Clinical Research
    Programs at the NCR Kimmel Cancer Center at Sibley Memorial Hospital
    Johns Hopkins University School of Medicine
    Washington, DC

    Consulting Agreements: AstraZeneca Pharmaceuticals LP, Caris Life Sciences, Celgene Corporation, Foundation Medicine, Halozyme Inc, Ipsen Biopharmaceuticals Inc, Merck, Merrimack Pharmaceuticals Inc, Perthera, Rafael Pharmaceuticals Inc, RenovoRx, Sirtex Medical Ltd; Contracted Research: AbbVie Inc, ARMO BioSciences, AstraZeneca Pharmaceuticals LP, Bavarian Nordic, Bayer HealthCare Pharmaceuticals, Boston Biomedical Inc, Bristol-Myers Squibb Company, Calithera Biosciences, Celgene Corporation, Celldex Therapeutics, Curegenix, FibroGen, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Halozyme Inc, Karyopharm Therapeutics, Lilly, Merck, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Regeneron Pharmaceuticals Inc, Tesaro, A GSK Company; Ownership Interest: Perthera; Patent Pending: AbbVie Inc.

    Tammy Triglianos, RN, MS, ANP-BC, AOCNP
    GI Oncology Nurse Practitioner
    Lineberger Comprehensive Cancer Center
    The University of North Carolina Division of Oncology
    Department of Medicine, University of North Carolina
    Chapel Hill, North Carolina

    No financial interests or affiliations to disclose.

    Deborah Wright, MSN, APRN, CNS
    Phase I Clinical Nurse Specialist
    Oncology Infusion APP Team Lead
    Stephenson Cancer Center
    University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma

    No financial interests or affiliations to disclose.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME/CNE activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc, Tolero Pharmaceuticals and Verastem Inc.

    RTP CNE (NCPD) PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Merck.

    Release date: September 2020
    Expiration date: September 2021

    There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):